Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines.
Classification
Consensus
Guideline
Intra-arterial chemotherapy
Intra-vitreal chemotherapy
Intraocular retinoblastoma
Intravenous chemotherapy
Journal
Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442
Informations de publication
Date de publication:
13 Apr 2024
13 Apr 2024
Historique:
received:
22
01
2024
accepted:
01
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Retinoblastoma (RB) is the most common childhood intraocular malignancy. Delayed presentation due to a lack of awareness and advanced intraocular tumors are a common scenario in low-middle income countries (LMICs). Remarkable treatment advances have been made in the past few decades allowing globe salvage in advanced intraocular RB (IORB) including systemic chemotherapy with focal consolidation and targeted treatments like intraarterial chemotherapy and intravitreal chemotherapy. However, a lack of availability and affordability limits the use of such advances in LMICs. External beam radiotherapy, despite risk of second cancers in RB with germline mutations, still remains useful for recalcitrant RB not responding to any other treatment. When choosing conservative treatment for advanced IORB, the cost and long duration of treatment, morbidity from multiple evaluation under anesthesias (EUAs), side effects of treatment and risk of treatment failure need to be taken into account and discussed with the parents. In this article, the authors discuss the ICMR consensus guidelines on the management of IORB.
Identifiants
pubmed: 38609685
doi: 10.1007/s12098-024-05095-0
pii: 10.1007/s12098-024-05095-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Références
Indian Council of Medical Research. Consensus Document for Management of Retinoblastoma. 2023. Available at: https://main.icmr.nic.in/sites/default/files/whats_new/Draft_Consensus_Document_for_Management_of_Retinoblastoma.pdf . Accessed on 22 Jan 2024.
Meel R, Radhakrishnan V, Bakhshi S. Current therapy and recent advances in the management of retinoblastoma. Indian J Med Paediatr Oncol. 2012;33:80–8.
pubmed: 22988349
pmcid: 3439795
Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68:2356–65.
pubmed: 33120616
pmcid: 7774148
Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.
pubmed: 16996605
Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies—an analysis of impact. Ophthalmic Genet. 2009;30:40–4.
pubmed: 19172510
Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.
pubmed: 10561222
Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119:1269–72.
pubmed: 11545631
Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95:1583–7.
pubmed: 3211467
Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in northern India. Ocul Oncol Pathol. 2017;4:23–32.
pubmed: 29344495
pmcid: 5757564
Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Palkonda VAR. Retinoblastoma in India: clinical presentation and outcome in 1,457 patients (2,074 eyes). Retina. 2019;39:379–91.
pubmed: 29210937
Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453–60.
pubmed: 24656794
Meel R, Bakhshi S, Pushker N, Vishnubhatla S. Randomized, controlled trial in groups C and D retinoblastoma. Ophthalmology. 2015;122:433–5.
pubmed: 25439612
Berry JL, Munier FL, Gallie BL, et al. Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatr Blood Cancer. 2021;68:e28964.
pubmed: 33624399
pmcid: 8049511
Fabian ID, Stacey AW, Johnson KC, et al. Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye. Br J Ophthalmol. 2018;102:265–71.
pubmed: 28659391
Scelfo C, Francis JH, Khetan V, et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol. 2017;10:961–7.
pubmed: 28730089
pmcid: 5515152
Kiratli H, Koç İ, Inam O, Varan A, Akyüz C. Retrospective analysis of primarily treated group D retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:2225–31.
pubmed: 29961117
Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404.
pubmed: 18342944
Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017. https://doi.org/10.1002/pbc.26696 .
doi: 10.1002/pbc.26696
pubmed: 29218818
pmcid: 7446180
Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapyin 76 eyes. Ophthalmology. 2009;116:544–51.
pubmed: 19157557
Rao R, Honavar SG, Reddy VP. Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. Br J Ophthalmol. 2019;103:1856–61.
pubmed: 30796055
Weng PY, Chen SH, Kao LY, et al. Clinical spectrum and treatment outcome of retinoblastoma with Group D and E diseases: a single institution retrospective review. Medicine. 2020;99:e22201.
pubmed: 32957352
pmcid: 7505397
Temming P, Viehmann A, Biewald E, Lohmann DR. Sporadic unilateral retinoblastoma or first sign of bilateral disease? Br J Ophthalmol. 2013;97:475–80.
pubmed: 23355526
Abramson DH, Servodidio CA. Retinoblastoma in the first year of life. Ophthalmic Paediatr Genet. 1992;13:191–203.
pubmed: 1488219
Hussain Z. Impact of laterality on cumulative survival in patients diagnosed with retinoblastoma: a retrospective cohort analysis of 1925 cases in the surveillance, epidemiology, and end results (SEER) program. Clin Ophthalmol. 2021;15:991–1001.
pubmed: 33707938
pmcid: 7943541
Meel R, Kashyap S, Bakhshi S, Bajaj MS, Wadhwani M. Retinoblastoma in children older than 6 years of age. Ocul Oncol Pathol. 2020;6:395–404.
pubmed: 33447589
pmcid: 7772882
Kashyap S, Meel R, Pushker N, et al. Phthisis bulbi in retinoblastoma. Clin Exp Ophthalmol. 2011;39:105–10.
pubmed: 21040312
Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Héon E. Management and outcome of unilateral retinoblastoma. J AAPOS. 2009;13:546–50.
pubmed: 20006813
El Zomor H, Nour R, Saad A, et al. Unilateral retinoblastoma; natural history and an age-based protocol in 248 patients. Eye (Lond). 2021;35:2564–72.
pubmed: 33188294
Pérez V, Sampor C, Rey G, et al. Treatment of nonmetastatic unilateral retinoblastoma in children. JAMA Ophthalmol. 2018;136:747–52.
pubmed: 29799944
pmcid: 6136048
Fabian ID, Shah V, Kapelushnik N, et al. Examinations under anaesthesia as a measure of disease burden in unilateral retinoblastoma: the London experience. Br J Ophthalmol. 2020;104:17–22.
pubmed: 30862620
Chantada G, Luna-Fineman S, Sitorus RS, et al; SIOP-PODC Graduated-Intensity Retinoblastoma Guidelines Writing Committee. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013;60:719–27.
pubmed: 23335388
Kaliki S, Shields CL, Eagle RC Jr, Iram S, Shields JA. High-risk intraocular retinoblastoma: comparison between Asian Indians and Americans from two major referral centers. Retina. 2018;38:2023–9.
pubmed: 28834944
Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer. 2012;58:356–61.
pubmed: 21721113
Kashyap S, Sethi S, Meel R, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med. 2012;136:190–3.
pubmed: 22288967
Sastre X, Chantada GL, Doz F, et al; International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133:1199–202.
pubmed: 19653709
Kashyap S, Singh L, Kumar N, et al. Combined association of massive choroidal and optic nerve invasion as a prognostic relevance in primary retinoblastoma: a 10-year study. Asia Pac J Clin Oncol. 2021;17:e100–8.
pubmed: 32710815
Messmer EP, Heinrich T, Höpping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastasis in patients with retinoblastoma. Ophthalmology. 1991;98:136–41.
pubmed: 2008269
Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.
pubmed: 12096963
Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.
pubmed: 22084213
Ye H, Du Y, Chen R, et al. The potential benefit of three vs. six cycles of carboplatin, etoposide, and vincristine in post enucleation high-risk patients with IRSS stage I retinoblastoma. Curr Eye Res. 2016;41:1507–12.
pubmed: 27158739
Rishi P, Agarwal A, Chatterjee P, et al. Intra-arterial chemotherapy for retinoblastoma: four-year results from tertiary center in India. Ocul Oncol Pathol. 2020;6:66–73.
pubmed: 32002408
Francis JH, Abramson DH, Ji X, et al. Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy. JAMA Ophthalmol. 2017;135:1426–9.
pubmed: 29098285
pmcid: 6583521
Mohanan A, Meel R, Venkatesh P, Kashyap S. Retinal tumour outcome with IVC in retinoblastoma. Eye. 2021;35:2046–7.
pubmed: 32665672
Kaliki S, Mittal P, Mohan S, et al. Bilateral advanced (group D or E) intraocular retinoblastoma: outcomes in 72 Asian Indian patients. Eye (Lond). 2019;33:1297–304.
pubmed: 30932036
Abramson DH, Marr BP, Francis JH, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (Tandem therapy). PLoS One. 2016;11:e0156806.
pubmed: 27258771
pmcid: 4892546